文献速递胃肠外科围术期管理与 ERAS

胃肠肿瘤手术围术期营养补充优化:随机安慰剂对照可行性临床试验

Perioperative optimization with nutritional supplements in patients undergoing gastrointestinal surgery for cancer: A randomized, placebo-controlled feasibility clinical trial.
PubMed 文献 · Surgery · 2022-05-21

该单中心随机预试验在胃肠肿瘤手术患者中比较围术期序贯营养补充与安慰剂,主要终点为入组率。18个月内筛查495例,144例符合条件,71例同意入组,入组率为49%(95%CI 41%-57%)。参与者中位总依从率为80%,两组术后并发症相似,对照组感染性并发症比例较高。

要点

  • 胃肠肿瘤手术患者围术期序贯营养补充的预试验入组率为49%。
  • 参与者对研究营养包的中位总依从率为80%。
  • 对照组感染性并发症比例高于干预组(52% vs 35%)。

核心结论

  • 预试验结果提示开展更大规模III期试验是可行的。
  • 术后感染性并发症常见,可作为合适的关注结局。

研究设计与样本

  • 单中心随机预试验,比较围术期营养补充与安慰剂,安慰剂与补充剂比例为1:1。
  • 干预按顺序包括:术前第30-6天蛋白质补充、术前第5-1天及术后第1-5天富含精氨酸和ω-6的蛋白质补充、手术日碳水化合物负荷。
  • 主要终点为入组率,次要终点包括对研究补充剂的依从性(目标为总包数的≥70%)。

主要发现

  • 18个月内筛查495例,144例符合条件,71例同意参与,入组率为71/144(49%,95%CI 41%-57%)。
  • 拒绝参与最常见原因为「负担过重」(34%)。
  • 参与者对研究营养包的中位总依从率为80%。
  • 方案修改(将入组至手术间隔从4周缩短至2周、缩短基线评估时长)未影响入组率或依从性。
  • 术后并发症对照组为18/31(58%,95%CI 4-74),干预组为22/34(65%,95%CI 48-79);感染性并发症对照组为16/31(52%),干预组为12/34(35%)。

临床怎么用

  • 围术期序贯营养补充方案在胃肠肿瘤手术患者中可行,但入组负担是主要障碍。
  • 术后感染性并发症可作为未来III期试验的关注结局。

局限性

  • 本研究为单中心预试验,样本量小,结果需更大规模试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Perioperative nutritional supplementation may improve outcomes. Trials have not investigated the role of combination strategy using different types of nutritional supplements. METHODS: We conducted a single-site randomized pilot trial, among gastrointestinal cancer patients undergoing surgery, comparing perioperative nutritional supplements versus placebo (1 placebo to each supplement), to determine feasibility of a larger trial. Intervention, administered in sequence, included: protein supplementation (preoperative day 30-6), protein supplementation rich in arginine and omega-6 (preoperative day 5-1, and postoperative day 1-5), and carbohydrate loading (surgery day). Primary outcome was enrollment. Secondary outcomes included participant compliance with study supplements (target ≥70% of total packets). We planned protocol modifications to improve enrollment and compliance. Postoperative complications were described. RESULTS: Over 18 months, 495 patients were screened, 144 were deemed eligible, and 71 consented to participate, resulting in an enrollment fraction of 71/144 (49%, 95% confidence interval: 41%-57%). 'Too much burden' was the most common reason for refusal to participate (34%). Participants' median overall compliance with study packets was 80%. Protocol modifications (decreasing the interval from enrollment to surgery from 4 to 2 weeks and decreasing length of baseline assessment) did not impact enrollment or compliance. Postoperative complications were similar between control (18/31 [58%, 95% confidence interval: 4-74]), and intervention (22/34 [65%, 95% confidence interval: 48-79]) arms, with a higher proportion of infectious complications in the control arm (16/31, 52% vs 12/34, 35%). CONCLUSION: Results from this pilot suggest a larger phase III trial is feasible. Postoperative infectious complications were common, making this a suitable outcome of interest.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Serrano PE, Parpia S, Simunovic M, et al. Perioperative optimization with nutritional supplements in patients undergoing gastrointestinal surgery for cancer: A randomized, placebo-controlled feasibility clinical trial. Surgery. 2022. PMID: 35606184. doi:10.1016/j.surg.2022.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。